Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
Courses of treatment with a combination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388) (850 mg/m2), cyclophosphamide (750 mg/m2), and vincristine (2.0 mg/m2) were given intravenously in single doses to patients with metastatic malignant melanoma. Treatment was repeated at 4-week intervals. Objective responses were observed in five of 20 patients (25%), indicating that treatment with this drug combination is at least as effective as treatment with NSC-45388 alone in either 5-day courses or intermittent, high-dose, single injections. The toxicity resulting from the combined treatment, although somewhat greater than that reported with the 5-day courses of NSC-45388, is acceptable and much less severe than that found with the single, high-dose schedule. Although the combination does not appear to increase the tumor response rate, it does maintain the advantage of a brief hospitalization for the patient.
Gardere
S
S
Department of Medicine, University of Toronto, Canada.
Hussain
S
S
Cowan
D H
DH
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003606:Dacarbazine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage*
D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide